Lannett Company, Inc. (AMEX:LCI) today reported financial results
for the fiscal 2007 third quarter and nine months ended March 31,
2007. For the third quarter of fiscal 2007, net sales were $20.3
million, compared with $15.7 million for the fiscal 2006 third
quarter. Net income was $0.2 million, or $0.01 per basic and
diluted share. This compares with fiscal 2006 third quarter net
income of $1.3 million, or $0.05 per basic and diluted share. For
the nine months ended March 31, 2007, net sales were $65.2 million,
compared with $44.6 million for the same period in the prior year.
Net income was $2.8 million, or $0.12 per basic and diluted share.
This compares with the prior year period net income of $4.1
million, or $0.17 per basic and diluted share. �We have
successfully grown our top line with increased sales of distributed
products, as a result of the strategic alliances formed since the
beginning of last year,� said Arthur Bedrosian, president and chief
executive officer of Lannett. �However, sales of in-house
manufactured products, which typically carry higher margins, have
been restrained due to the delays we continue to experience in
receiving drug approvals from the FDA. We fully expect our pending
product applications to eventually be approved by the FDA. In the
meantime, we are devoting increased resources to expanding our
pipeline with an active drug development program.� For the third
quarter of fiscal 2007, gross profit was $6.3 million, or 31% of
net sales, compared with $6.3 million, or 40% of net sales, in the
third quarter of fiscal 2006. Research and development expenses
increased to $2.3 million from $1.3 million in the same period of
fiscal 2006. SG&A expenses were $3.2 million, compared with
$2.6 million, in last year�s third quarter. Amortization expense
was $0.4 million for the third quarter of both fiscal 2007 and
2006. For the nine months ended March 31, 2007, gross profit was
$21.1 million, or 32% of net sales, compared to $20.3 million, or
46% of net sales, for the same period in the prior year. Research
and development expenses increased to $5.6 million from $4.8
million in the same period of the prior year. SG&A expenses
increased to $9.5 million, compared with $7.3 million, in the same
period last year. Amortization expense was $1.3 million for the
first nine months of both fiscal 2007 and 2006. About Lannett
Company: Lannett Company, founded in 1942, develops, manufactures,
packages, markets and distributes generic pharmaceutical products
for a wide range of indications. For more information, visit the
company�s website at www.lannett.com. This news release contains
certain statements of a forward-looking nature relating to future
events or future business performance. Any such statements,
including, but not limited to, pending ANDAs and products in
various stages of development, whether expressed or implied, are
subject to risks and uncertainties which can cause actual results
to differ materially from those currently anticipated due to a
number of factors which include, but are not limited to, the
difficulty in predicting the timing or outcome of FDA or other
regulatory approvals or actions, the ability to successfully
commercialize products upon approval, Lannett�s estimated or
anticipated future financial results, future inventory levels,
future competition or pricing, future levels of operating expenses,
product development efforts or performance, and other risk factors
discussed in the company�s Form 10-K and other documents filed with
the Securities and Exchange Commission from time to time. These
forward-looking statements represent the company's judgment as of
the date of this news release. The company disclaims any intent or
obligation to update these forward-looking statements. LANNETT
COMPANY, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF
OPERATIONS � � � For the Three Months Ended For the Nine Months
Ended (UNAUDITED) (UNAUDITED) March 31, March 31, March 31, March
31, 2007� 2006� 2007� 2006� � Net sales $ 20,302,576� $ 15,737,180�
$ 65,186,747� $ 44,607,481� Cost of sales � 14,032,421� �
9,404,156� � 44,123,101� � 24,330,916� Gross profit 6,270,155�
6,333,024� 21,063,646� 20,276,565� � Research and development
2,269,677� 1,252,108� 5,586,213� 4,814,186� Selling, general, &
administrative 3,192,877� 2,554,595� 9,537,333� 7,332,135�
Amortization of intangible assets � 446,166� � 446,166� �
1,338,498� � 1,338,499� � Operating income 361,435� 2,080,155�
4,601,602� 6,791,745� � Other income � 22,898� � 30,906� � 101,308�
� 83,869� � Income before taxes 384,333� 2,111,061� 4,702,910�
6,875,614� � Income tax expense � 153,733� � 856,402� � 1,882,644�
� 2,752,335� � Net income $ 230,600� $ 1,254,659� $ 2,820,266� $
4,123,279� � Earnings per share: Basic $ 0.01� $ 0.05� $ 0.12� $
0.17� Diluted $ 0.01� $ 0.05� $ 0.12� $ 0.17� � Shares used to
calculate earnings per share: Basic � 24,164,385� � 24,135,723� �
24,155,556� � 24,126,588� Diluted � 24,218,406� � 24,201,162� �
24,205,347� � 24,174,198� LANNETT COMPANY, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS � � � (unaudited) March 31,
June 30, 2007� 2006� Assets: Current Assets: Cash $ 4,316,849� $
468,359� Trade accounts receivable, net 29,057,307� 24,921,671�
Inventories 13,058,531� 11,476,503� Prepaid taxes 2,846,023�
3,212,511� Other current assets 1,934,823� 1,946,631� Deferred tax
asset � 1,461,172� � 1,461,172� Total current assets 52,674,705�
43,486,847� � Property and equipment, net 20,847,240� 19,645,549� �
Investment securities-available-for-sale 3,780,094� 5,621,609� Note
Receivable 10,509,736� 3,182,498� Deferred tax asset 16,169,695�
18,070,674� Intangible asset, net 12,492,668� 13,831,168�
Construction in progress 746,700� 1,955,508� Other assets �
231,832� � 198,211� Total Assets $ 117,452,670� $ 105,992,064� � �
Liabilities and Shareholders' Equity: Current liabilities $
28,084,652� $ 20,040,608� Long-term debt, less current portion
7,193,145� 7,649,806� Deferred income taxes and other liabilities
2,545,734� 2,545,734� Shareholders' equity � 79,629,139� �
75,755,916� Total Liabilities and Shareholders' Equity $
117,452,670� $ 105,992,064�
London Clubs (AMEX:LCI)
過去 株価チャート
から 6 2024 まで 7 2024
London Clubs (AMEX:LCI)
過去 株価チャート
から 7 2023 まで 7 2024